Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
Androgen receptor inhibitor
DRUG CLASS:
Androgen receptor inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
enzalutamide capsule (78)
darolutamide (14)
bicalutamide (13)
flutamide (4)
EPI-7170 (1)
ONCT-534 (1)
SID 3712502 (1)
rezvilutamide (0)
MVI-118 (0)
enzalutamide capsule (78)
darolutamide (14)
bicalutamide (13)
flutamide (4)
EPI-7170 (1)
ONCT-534 (1)
SID 3712502 (1)
rezvilutamide (0)
MVI-118 (0)
›
Associations
(114)
News
Trials
Search handles
@AzadOncology
@CParkMD
@DineshMakuny
@DrBonillaOnc
@DrChoueiri
@DrGattiMays
@DrYukselUrun
@EllisLab_
@LoebStacy
@TiansterZhang
@a_nourallah
@amerseburger
@montypal
@nataliagandur
@neerajaiims
@shilpaonc
@teamoncology
@tompowles1
@urogomez_
@weldeiry
Search handles
@AzadOncology
@CParkMD
@DineshMakuny
@DrBonillaOnc
@DrChoueiri
@DrGattiMays
@DrYukselUrun
@EllisLab_
@LoebStacy
@TiansterZhang
@a_nourallah
@amerseburger
@montypal
@nataliagandur
@neerajaiims
@shilpaonc
@teamoncology
@tompowles1
@urogomez_
@weldeiry
Filter by
Latest
8ms
.@neerajaiims, of @huntsmancancer, speaks on the significance of the approval and how the combination of talazoparib and enzalutamide will fit into the treatment landscape of HRR gene–mutated mCRPC. #pcsm https://t.co/xbusmBgW8j (@OncLive)
8 months ago
HRD (Homologous Recombination Deficiency)
|
Talzenna (talazoparib) • enzalutamide capsule
8ms
For patients with HRR gene–mutated mCRPC, additional data supporting the use of the combination of the PARP inhibitor talazoparib with enzalutamide is a welcome signal in the field. @neerajaiims @huntsmancancer #pcsm https://t.co/QMXZaAaaoU (@OncLive)
8 months ago
Clinical
|
HRD (Homologous Recombination Deficiency)
|
Talzenna (talazoparib) • enzalutamide capsule
8ms
Agarwal Discusses FDA Approval of Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC @neerajaiims @huntsmancancer @ASCO #ASCO23 #pcsm https://t.co/IIAaAi2fho (@OncLive)
8 months ago
FDA event
|
HRD (Homologous Recombination Deficiency)
|
Talzenna (talazoparib) • enzalutamide capsule
8ms
"Efficacy and safety of darolutamide in combination with ADT and docetaxel by disease volume and disease risk in the #ARASENS trial. @fizazi_karim @GustaveRoussy joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/UTSvewcfNi @Bayer" (@urotoday)
8 months ago
Combination therapy • Clinical
|
docetaxel • Nubeqa (darolutamide)
8ms
The addition of Talazoparib(PARPi) to enzalutamide in CRPC has most marked effects in BRCA+ve tumors. Effects in the remaining HRR population are marginal. This is largely consistent with previous data for PARPi in CRPC, supporting the ODAC decision on olaparib #ACScancerchat (@tompowles1)
8 months ago
ODAC
|
BRCA (Breast cancer early onset)
|
Lynparza (olaparib) • Talzenna (talazoparib) • enzalutamide capsule
9ms
Agree! In the context of the addition of Talazoparib (PARPi) to enzalutamide in castration-resistant prostate cancer (CRPC), it appears that the most significant effects are observed in tumors that are BRCA positive. However, the effects in the remaining population with… https://t.co/j3Kyx4NTSd (@nataliagandur)
9 months ago
BRCA (Breast cancer early onset)
|
Talzenna (talazoparib) • enzalutamide capsule
9ms
Here, @DrChoueiri MD, joins the @OncBrothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent updates from TALAPRO-2, which studied #talazoparib plus #enzalutamide in first-line #mCRPC. #pcsm | @DanaFarber https://t.co/7zhmpcYZkN (@TargetedOnc)
9 months ago
Clinical
|
Talzenna (talazoparib) • enzalutamide capsule
9ms
Deep PSA response following the addition of darolutamide to ADT and docetaxel in #ARASENS. Fred Saad, MD, FRCS @chumontreal and @zklaassen_md @GACancerCenter discuss the trial's transformative impact on #ProstateCancer treatment. #WatchNow > https://t.co/az1qfisj2m (@urotoday)
9 months ago
docetaxel • Nubeqa (darolutamide)
9ms
#DEAR Comparative real-world evidence on darolutamide, enzalutamide, and apalutamide for patients with #nmCRPC in the #UnitedStates. Neal Shore, MD, FRCS @AtlanticUrology and @CaPsurvivorship @DanaFarber discuss on UroToday > https://t.co/XK2NvCkQsU (@urotoday)
9 months ago
Clinical • HEOR • Real-world evidence • Real-world
|
enzalutamide capsule • Nubeqa (darolutamide) • Erleada (apalutamide)
9ms
Dr. Cora Sternberg (@cnsternberg) sat down with @urotoday to discuss the TALAPRO-2 #ClinicalTrial evaluating talazoparib and enzalutamide for metastatic castration-resistant #ProstateCancer. Results from this study recently led to approval by the @US_FDA: https://t.co/WElMYP2tba (@WCMGUcancer)
9 months ago
Clinical • Metastases
|
Talzenna (talazoparib) • enzalutamide capsule
9ms
#EMBARK trial shows promising results for high-risk #ProstateCancer treatment, enzalutamide's impact on MFS. Join Neal Shore, MD, FACS @AtlanticUrology and @CaPsurvivorship @DanaFarber as they discuss on UroToday > https://t.co/LRUuRj9j8s #AUA23 @AstellasUS @pfizer (@urotoday)
9 months ago
enzalutamide capsule
9ms
Join @CaPsurvivorship @DanaFarber & @alaccetti @MSKCancerCenter as they discuss the promising data on the combination of enzalutamide with EPI-7386 in #mCRPC pts and this new approach to disrupting the androgen receptor signaling pathway > https://t.co/gOUyvJjXUG @EssaPharma (@urotoday)
9 months ago
Clinical
|
enzalutamide capsule • masofaniten (EPI-7386)
9ms
🧐Number Needed to #Treat and to #Harm analyses to #compare outcomes in castration-sensitive #prostatecancer patients treated w/ #apalutamide or #enzalutamide ➡️ including data from ARCHES, ENZAMET and TITAN phase 3⃣ trials 🔗https://t.co/6D7ZJsYVLE #TJ🔖 @nataliagandur (@TumoriJ)
9 months ago
Clinical
|
enzalutamide capsule • Erleada (apalutamide)
9ms
The efficacy of enzalutamide + androgen deprivation therapy in oligometastatic hormone-sensitive #ProstateCancer: a post hoc analysis of #ARCHES. #BeyondTheAbstract with @AarmstrongDuke @DukeCancer and @AzadOncology @PeterMacCC on UroToday > https://t.co/8ou1jaeAic @EUplatinum (@urotoday)
9 months ago
Clinical • Retrospective data • Metastases
|
enzalutamide capsule
9ms
From @gr8straj , @EliotBlatt & co-workers: Identification of the central role of #antioxidant programs in enzalutamide-resistant #ProstateCancer 🔬https://t.co/5i0Bv2FXmv (@oncogenejournal)
9 months ago
enzalutamide capsule
9ms
FDA Approves Talazoparib Plus Enzalutamide for HRR Gene–Altered mCRPC https://t.co/tZeYsWh070 a través de @onclive (@urogomez_)
9 months ago
FDA event
|
HRD (Homologous Recombination Deficiency)
|
Talzenna (talazoparib) • enzalutamide capsule
9ms
FDA Approves #Talazoparib Plus #Enzalutamide for HRR Gene–Altered #mCRPC https://t.co/5FyjMzzPcY via @onclive (@a_nourallah)
9 months ago
FDA event
|
HRD (Homologous Recombination Deficiency)
|
Talzenna (talazoparib) • enzalutamide capsule
9ms
Our paper identifying that antioxidant programs are essential for enzalutamide-resistant prostate cancer is online now. Go check it out! @gr8straj @RJDLab @Ram_Mani_PhD @jodebon @oncogenejournal https://t.co/hXGLic1xOX (@EliotBlatt)
9 months ago
enzalutamide capsule
9ms
So pleased (& a little proud) to see U.S. FDA approval of Enzalutamide & Talazoparib in HRR-deficient 1L mCRPC - @AzadOncology #drugs #Enzalutamide #Talazoparib #usfda #cancer #oncology #oncodaily https://t.co/0JiaY9mS8d (@oncodaily)
9 months ago
FDA event
|
Talzenna (talazoparib) • enzalutamide capsule
9ms
@US_FDA approves Talazoparib (Talzenna) + Enzalutamide for mCRPC #prostatecancer with HRR mutations! We are back to precision oncology 👏@neerajaiims @OncoAlert @PCFnews @urotoday @Uroweb @EfstathiouEleni @onkowissen @PfizerOncMed @Uromigos @DrYukselUrun https://t.co/1ociZHTVVe (@amerseburger)
9 months ago
FDA event
|
Talzenna (talazoparib) • enzalutamide capsule
9ms
Efficacy and safety of darolutamide in combination with ADT and docetaxel by disease volume and disease risk in the #ARASENS trial. @fizazi_karim @GustaveRoussy joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/UTSvewcfNi @Bayer ()
9 months ago
Combination therapy • Clinical
|
docetaxel • Nubeqa (darolutamide)
9ms
FDA Approves Talazoparib Plus Enzalutamide for HRR Gene–Altered mCRPC https://t.co/8XMEegAIzx via @onclive (@DrBonillaOnc)
9 months ago
FDA event
|
HRD (Homologous Recombination Deficiency)
|
Talzenna (talazoparib) • enzalutamide capsule
9ms
Congrats @neerajaiims and team on this new approval of talazoparib-enzalutamide for mCRPC patients with HRR mutations! @NeliMUlrich @Huntsman_GU @PCFnews @charlesryanmd @AzadOncology (@shilpaonc)
9 months ago
Clinical
|
Talzenna (talazoparib) • enzalutamide capsule
9ms
Wonderful to see this approval arrive not long after @neerajaiims @huntsmancancer's stellar presenation at @ASCO #GU23 & follow-up paper in @TheLancet! #TALAPRO2 offers a new std of care (#talazoparib w #enzalutamide) for metastatic castration-resistant #prostatecancer with HRR… https://t.co/rXw643BBcd (@montypal)
9 months ago
Metastases
|
Talzenna (talazoparib) • enzalutamide capsule
9ms
Wonderful to see this approval arrive not long after @neerajaiims @huntsmancancer's stellar presentation at @ASCO #GU23 & follow-up paper in @TheLancet! #TALAPRO2 offers a new std of care (#talazoparib w #enzalutamide) for metastatic castration-resistant #prostatecancer with HRR… https://t.co/GtSKG2OD0Y (@montypal)
9 months ago
Metastases
|
Talzenna (talazoparib) • enzalutamide capsule
10ms
Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer https://t.co/t9O2PrEeg5 @tanyawildes @WilliamDale_MD @rochgerionc @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Frailty #Efficacy (@JGeriOnc)
10 months ago
Clinical • Metastases
|
enzalutamide capsule • abiraterone acetate
10ms
@neerajaiims @huntsmancancer and @CaPsurvivorship @DanaFarber discuss results from the #TALAPRO-2 phase 3 trial, showing a 36% reduction in risk of radiographic progression in patients with #mCRPC treated with talazoparib and enzalutamide. #WatchNow > https://t.co/pe2ho6oXbo (@urotoday)
10 months ago
Clinical
|
Talzenna (talazoparib) • enzalutamide capsule
10ms
🌟The Benefit of the Addition of Talazoparib to Enzalutamide in First Line Treatment for mCRPC #TALAPRO2 by @neerajaiims on @urotoday. 🌟Exciting advancements in #prostatecancer research and potential for improved outcomes! #oncology #medicalresearch https://t.co/kDDUZWla56 (@nataliagandur)
10 months ago
Clinical
|
Talzenna (talazoparib) • enzalutamide capsule
10ms
What are you doing for these apocrine tnbc? Have seen two in my clinic…colleague saw response to casodex in advanced setting but patient had to pay out of pocket (@KatFish07740556)
10 months ago
Clinical • Metastases
|
bicalutamide
10ms
TALAPRO-2 involving enzalutamide with talazoparib, confirmed statistical benefit for patients with castrate-resistant prostate cancer. This trial was run at TKCC, and we are thrilled with the results. A special thank you to all involved @AnthonyMJoshua https://t.co/oHhxrXMnPa (@kinghorncancer)
10 months ago
Clinical
|
Talzenna (talazoparib) • enzalutamide capsule
10ms
Now in @EUplatinum: ➡️ODENZA trial - open-label, x-over study of Darolumatimde vs Enzalutamide ➡️Less fatigue & memory issues with Daro ➡️But no diff in pt preference ➡️ My take: both Daro & Enza excellent options for pts with mCR #prostatecancer (@AzadOncology)
10 months ago
Clinical
|
enzalutamide capsule
10ms
#EMBARK trial shows promising results for high-risk #ProstateCancer treatment, enzalutamide's impact on MFS. Join Neal Shore, MD, FACS @AtlanticUrology and @CaPsurvivorship @DanaFarber as they discuss on UroToday > https://t.co/LRUuRj8LiU #AUA23 @AstellasUS @pfizer (@urotoday)
10 months ago
enzalutamide capsule
10ms
Join @CaPsurvivorship @DanaFarber & @alaccetti @MSKCancerCenter as they discuss the promising data on the combination of enzalutamide with EPI-7386 in #mCRPC pts and this new approach to disrupting the androgen receptor signaling pathway > https://t.co/gOUyvJjXUG @EssaPharma (@urotoday)
10 months ago
Clinical
|
enzalutamide capsule • masofaniten (EPI-7386)
10ms
Patients with nmCRPC who received darolutamide were observed to have a longer time to treatment discontinuation and progression to metastatic castration-resistant disease than those who received enzalutamide or apalutamide. @CaPsurvivorship @DanaFarber https://t.co/L1S1M3wm3G (@OncLive)
10 months ago
Clinical • Metastases
|
enzalutamide capsule • Nubeqa (darolutamide) • Erleada (apalutamide)
10ms
Alicia K. Morgans, MD, MPH, and Karim Fizazi, MD, on Prostate Cancer: Phase III Results on Talazoparib Plus Enzalutamide as First-Line Treatment https://t.co/GqOmOEvo3h #pcsm #prostatecancer #oncology #ASCO23 @CaPSurvivorship @DanaFarber @GustaveRoussy (@ASCOPost)
10 months ago
Clinical
|
Talzenna (talazoparib) • enzalutamide capsule
10ms
Oral EPI-7386 monotherapy in patients with #mCRPC. @RPachynski @WUSTLmed joins @CaPsurvivorship @DanaFarber to discuss this first-in-class N-terminal domain AR inhibitor that suppresses androgen activity through a novel mechanism of action > https://t.co/1V8Caa6lVK @EssaPharma (@urotoday)
10 months ago
Clinical
|
masofaniten (EPI-7386)
10ms
Concurrent chemo-hormonal therapy of enzalutamide and cabazitaxel in patients with #mCRPC: final analysis of ORR, rPFS, and OS. Presentation by @sokolova_md @OHSUKnight. #ASCO23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/4sC64atkDl @ASCO (@urotoday)
10 months ago
Clinical
|
enzalutamide capsule • cabazitaxel
10ms
Talazoparib + enzalutamide in metastatic castration-resistant #ProstateCancer #mCRPC: Safety analyses from the randomized, placebo-controlled, phase 3 #TALAPRO2 study. Presented by @AzadOncology @PeterMacCC. #ASCO23 written coverage by @tchandra_uromd > https://t.co/mam7BYi0vZ (@urotoday)
10 months ago
Clinical • Metastases
|
Talzenna (talazoparib) • enzalutamide capsule
10ms
#ASCO23: TALAPRO-2: Talazoparib + enzalutamide in the first-line setting significantly reduces the risk of progression or death by 55% among pts w/ HRR–deficient #mCRPC: https://t.co/eHBlENaRWG #ASCODailyNews #GUCSM #pcsm @vanderweelemd (@ASCO)
10 months ago
Clinical
|
Talzenna (talazoparib) • enzalutamide capsule
10ms
Great data showing no adverse events with dose escalation of #Enzalutamide (120) + #Relacorilant (150) treatment in metastatic castration resistant #prostatecancer patients. @ASCO #ASCO23 @UCCancerCenter @RandySweisMD (@UCCancerCenter)
10 months ago
Clinical • Adverse events • Metastases
|
enzalutamide capsule • relacorilant (CORT125134)
10ms
The one and only @fizazikarim presents the results of #TALAPRO2 Results in cohort 1 reported by @neerajaiims #ASCOGU23 and out @TheLancet ! In cohort 2: talazoparib + enzalutamide ⬆️rPFS and a trend towards ⬆️OS (immature) in #mCRPC with #HRRm (BRCA++) (@DrChoueiri)
10 months ago
BRCA (Breast cancer early onset)
|
Talzenna (talazoparib) • enzalutamide capsule
10ms
Darolutamide associated with lower risk of treatment discontinuation, longer time to progression to mCRPC and adverse events compared with enzalutamide and apalutamide in real-world cohort with nonmetastatic CRPC from urology practices -@CaPsurvivorship #asco23 (@LoebStacy)
10 months ago
Clinical • Adverse events • Real-world evidence • Real-world • Metastases
|
enzalutamide capsule • Nubeqa (darolutamide) • Erleada (apalutamide)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login